Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Thyrotoxicosis: HELP
Articles by Françoise Desbiez
Based on 2 articles published since 2008
||||

Between 2008 and 2019, Françoise Desbiez wrote the following 2 articles about Thyrotoxicosis.
 
+ Citations + Abstracts
1 Review Issues in amiodarone-induced thyrotoxicosis: Update and review of the literature. 2019

Maqdasy, Salwan / Benichou, Thomas / Dallel, Sarah / Roche, Béatrice / Desbiez, Françoise / Montanier, Nathanaëlle / Batisse-Lignier, Marie / Tauveron, Igor. ·Service d'endocrinologie, diabétologie et maladies métaboliques, CHU Clermont-Ferrand, 63003 Clermont-Ferrand, France; Laboratoire GReD, UMR Université Clermont Auvergne-CNRS 6293, Inserm U1103, BP 10448, 63177 Aubière, France. Electronic address: smaqdasy@chu-clermontferrand.fr. · Service d'endocrinologie, diabétologie et maladies métaboliques, CHU Clermont-Ferrand, 63003 Clermont-Ferrand, France. · Service d'endocrinologie, diabétologie et maladies métaboliques, CHU Clermont-Ferrand, 63003 Clermont-Ferrand, France; Laboratoire GReD, UMR Université Clermont Auvergne-CNRS 6293, Inserm U1103, BP 10448, 63177 Aubière, France. ·Ann Endocrinol (Paris) · Pubmed #30236455.

ABSTRACT: Amiodarone, a benzofuranic iodine-rich pan-anti-arrhythmic drug, induces amiodarone-induced thyrotoxicosis (AIT) in 7-15% of patients. AIT is a major issue due to its typical severity and resistance to anti-thyroid measures, and to its negative impact on cardiac status. Classically, AIT is either an iodine-induced thyrotoxicosis in patients with abnormal thyroid (type 1), or due to acute thyroiditis in a "healthy" thyroid (type 2). Determination of the type of AIT is a diagnostic dilemma, as characteristics of both types may be present in some patients. As it is the main etiological factor in AIT, it is recommended that amiodarone treatment should be stopped; however, it may be the only anti-arrhythmic option, needing to be either continued or re-introduced to improve cardiovascular survival. Recently, a few studies demonstrated that amiodarone could be continued or re-introduced in patients with history of type-2 AIT. However, in the other patients, it is recommended that amiodarone treatment be interrupted, to improve response to thioamides and to alleviate the risk of AIT recurrence. In such patients, thyroidectomy is recommended once AIT is under control, allowing safe re-introduction of amiodarone.

2 Article Amiodarone-Induced Thyrotoxicosis Recurrence After Amiodarone Reintroduction. 2016

Maqdasy, Salwan / Batisse-Lignier, Marie / Auclair, Candy / Desbiez, Françoise / Citron, Bernard / Thieblot, Philippe / Roche, Béatrice / Lusson, Jean René / Tauveron, Igor. ·Service d'endocrinologie, diabétologie et maladies métaboliques, CHU Clermont-Ferrand, Clermont-Ferrand, France; UMR CNRS 6293, INSERM U1103, Génétique Reproduction et Développement, Université Clermont-Auvergne, Aubiere, France. Electronic address: smaqdasy@chu-clermontferrand.fr. · Service d'endocrinologie, diabétologie et maladies métaboliques, CHU Clermont-Ferrand, Clermont-Ferrand, France; UMR CNRS 6293, INSERM U1103, Génétique Reproduction et Développement, Université Clermont-Auvergne, Aubiere, France. · Service de Santé Publique, CHU Clermont-Ferrand, Clermont-Ferrand, France. · Service d'endocrinologie, diabétologie et maladies métaboliques, CHU Clermont-Ferrand, Clermont-Ferrand, France. · Service de cardiologie et maladies cardiovasculaires, CHU Clermont-Ferrand, Clermont-Ferrand, France. ·Am J Cardiol · Pubmed #26853955.

ABSTRACT: Reintroduction of amiodarone in patients with a history of amiodarone-induced thyrotoxicosis (AIT) is rarely used. To date, the risk of AIT recurrence after amiodarone reintroduction is unpredicted. The aim of the study was to evaluate the risk of AIT recurrence. Retrospectively, from 2000 to 2011, all euthyroid patients with a history of AIT with amiodarone reintroduction were included. Type and severity of the first AIT, amiodarone chronology, and thyroid function evolution after reintroduction of amiodarone were investigated: 46 of 172 patients with AIT history needed amiodarone reintroduction. At first AIT episode, the mean age was 62.2 ± 16 years with male gender predominance; 65% of patients were classified as type 1 AIT. AIT recurred in 14 patients (30%), 12 patients developed hypothyroidism (26%), and 20 patients remained euthyroid (44%). Characteristics of type 1 AIT during the first episode, namely briefer exposure period to amiodarone and longer duration of treatment to normalize thyroid hormones, were predictive of AIT recurrence; 73% of patients (8 of 11) with previous episode of type 1 AIT, who did not receive a preventive thioamide treatment, developed a second episode of AIT. Thioamide preventive treatment could be useful to prevent type 1 AIT recurrence. In conclusion, AIT recurrence after amiodarone reintroduction is 4 times more frequent in patients with type 1 AIT history. Thyroid ablation before amiodarone reintroduction in patients with a history of type 1 AIT is preferred. Preventive thioamide treatment could be suggested in patients with type 1 AIT history pending for surgery.